Univariate and multivariate analyses of prognostic factors in ICC (n=359)
| Variable | TTR | OS | ||
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Univariate analysis | ||||
| Age, year (≤50 vs >50) | 1.06 (0.79 to 1.43) | 0.689 | 1.29 (0.94 to 1.78) | 0.116 |
| Sex (female vs male) | 1.17 (0.92 to 1.50) | 0.2 | 1.07 (0.83 to 1.38) | 0.583 |
| HBsAg (negative vs positive) | 1.02 (0.79 to 1.33) | 0.872 | 0.72 (0.54 to 0.96) | 0.025 |
| AFP, ng/mL (≤20 vs >20) | 0.99 (0.68 to 1.43) | 0.941 | 0.84 (0.56 to 1.26) | 0.396 |
| CA19-9 (≤36 vs >36) | 1.51 (1.18 to 1.94) | 0.001 | 1.90 (1.46 to 2.48) | 0 |
| GGT, U/L (≤54 vs >54) | 1.63 (1.28 to 2.09) | 0 | 1.92 (1.48 to 2.48) | 0 |
| Liver cirrhosis (no vs yes) | 1.02 (0.77 to 1.36) | 0.88 | 0.83 (0.61 to 1.12) | 0.226 |
| Tumor size, cm (≤5 vs >5) | 1.59 (1.25 to 2.04) | 0 | 1.65 (1.28 to 2.14) | 0 |
| Tumor number (single vs multiple) | 2.36 (1.82 to 3.05) | 0 | 2.66 (2.03 to 3.47) | 0 |
| Microvascular/Bile duct invasion (no vs yes) | 1.25 (0.93 to 1.69) | 0.139 | 1.48 (1.10 to 1.97) | 0.009 |
| Lymphatic metastasis (no vs yes) | 2.41 (1.77 to 3.28) | 0 | 2.70 (1.96 to 3.72) | 0 |
| Tumor encapsulation (complete vs none) | 1.46 (1.03 to 2.05) | 0.033 | 1.46 (1.01 to 2.11) | 0.042 |
| Tumor differentiation (I+II vs III+IV) | 1.31 (1.03 to 1.67) | 0.028 | 1.43 (1.11 to 1.84) | 0.005 |
| TNM stage (I vs II+III+IV) | 2.29 (1.79 to 2.93) | 0 | 2.78 (2.14 to 3.61) | 0 |
| CD66b+ TANs (low vs high) | 1.61 (1.27 to 2.06) | 0 | 1.72 (1.34 to 2.22) | 0 |
| CD68+ TAMs (low vs high) | 1.55 (1.21 to 1.97) | 0 | 1.68 (1.30 to 2.16) | 0 |
| p-STAT3 (low vs high) | 1.50 (1.18 to 1.91) | 0.001 | 1.59 (1.23 to 2.05) | 0 |
| TANs and TAMs (both low vs both high) | 1.97 (1.46 to 2.67) | 0 | 2.25 (1.64 to 3.08) | 0 |
| Multivariate analysis | ||||
| HBsAg (negative vs positive) | NA | NA | 0.29 (0.53 to 0.97) | 0.718 |
| CA19-9 (≤36 vs >36) | 1.10 (0.85 to 1.43) | 0.481 | 1.39 (1.06 to 1.83) | 0.018 |
| GGT, U/L (≤54 vs >54) | 1.45 (1.12 to 1.87) | 0.005 | 1.52 (1.16 to 1.99) | 0.003 |
| Tumor size, cm (≤5 vs >5) | 1.37 (1.06 to 1.78) | 0.016 | 1.36 (1.03 to 1.79) | 0.033 |
| Tumor number (single vs multiple) | 1.97 (1.50 to 2.59) | 0 | 2.12 (1.61 to 2.81) | 0 |
| Microvascular/Bile duct invasion (no vs yes) | NA | NA | 1.26 (0.92 to 1.73) | 0.146 |
| Lymphatic metastasis (no vs yes) | 1.78 (1.29 to 2.45) | 0 | 1.94 (1.38 to 2.71) | 0 |
| Tumor encapsulation (complete vs none) | 1.43 (1.01 to 2.03) | 0.046 | 1.41 (0.97 to 2.06) | 0.073 |
| Tumor differentiation (I+II vs III+IV) | 1.25 (0.97 to 1.60) | 0.08 | 1.31 (1.01 to 1.70) | 0.042 |
| CD66b+ TANs (low vs high) | 1.59 (1.24 to 2.03) | 0 | 1.71 (1.31 to 2.22) | 0 |
| CD68+ TAMs (low vs high) | 1.52 (1.19 to 1.94) | 0.001 | 1.53 (1.18 to 1.98) | 0.001 |
| p-STAT3 (low vs high) | 1.48 (1.16 to 1.89) | 0.002 | 1.59 (1.23 to 2.05) | 0 |
| TANs and TAMs (both low vs both high) | 2.01 (1.48 to 2.73) | 0 | 2.28 (1.64 to 3.18) | 0 |
Cox proportional hazards regression model.
AFP, alpha-fetoprotein; CA19-9, carbohydrate antigen 19-9; GGT, gamma-glutamyl transferase; HBsAg, hepatitis B surface antigen; ICC, intrahepatic cholangiocarcinoma; NA, not available; OS, overall survival; TAM, tumor-associated macrophage; TAN, tumor-associated neutrophil; TNM, tumor, node, metastasis; ; TTR, time to recurrence.